Author

E. Toska

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. A. Ku· 1 shared A. Chang· 1 shared A. Dhogan· 1 shared A. E. Loats· 1 shared A. F. Fleming· 1 shared A. L. Wolfe· 1 shared A. Melnick· 1 shared A. Mottok· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Ku

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nuclear cholesterol is required for transcriptional repression by BASP1

A. E. Loats, S. Carrera, A. F. Fleming, A. R. E. Roberts, A. Sherrard, E. Toska, K. F. Medler, S. G. E. Roberts

This study shows that nuclear cholesterol is required for BASP1-mediated transcriptional repression by facilitating chromatin remodelling and gene-specific repression.

bioRxiv · Jan 24, 2021Biochemistry

UDP-glucose pyrophosphorylase 2, a regulator of glycosylation and glycogen, is essential for pancreatic cancer growth

A. L. Wolfe, Q. Zhou, E. Toska, J. Galeas, A. A. Ku, R. P. Koche, S. Bandyopadhyay, M. Scaltriti, C. B. Lebrilla, F. McCormick, S. E. Kim

This study identifies UGP2 as essential for pancreatic cancer growth by regulating glycogen and N-glycosylation, with potential therapeutic implications.

bioRxiv · Oct 13, 2020 · PreprintCancer Biology

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

P. Mondello, S. Tadros, M. Teater, L. Fontan, A. Chang, N. Jain, S. Singh, M. C. J. Ma, H. Yang, E. Toska, S. Alig, M. Durant, E. de Stanchina, A. Mottok, L. Nastoupil, , M. Green

This paper shows that HDAC3 inhibitors reverse CREBBP mutation-driven epigenetic changes in lymphoma, inhibiting tumor growth and restoring immune surveillance.

bioRxiv · Jan 27, 2019Cancer Biology